{"entity":{"id":"vittoria-biotherapeutics","kind":"company","name":"Vittoria Biotherapeutics","aka":["viTToria Biotherapeutics"],"tldr":"Vittoria Biotherapeutics makes CAR-T cell therapy, a patient's own immune cells engineered to attack cancer, for T-cell lymphoma, a cancer of the same kind of cell that CAR-T is made from. Its first product, VIPER-101, is in an early trial.","summary":"Vittoria Biotherapeutics, Inc., at 3675 Market Street, Philadelphia, is a clinical-stage company whose Senza5 platform modulates CD5 signalling and uses a five-day manufacturing process for autologous CAR-T cells. Its lead product VIPER-101 (Senza5 CART5) is a gene-edited, autologous, dual-population CD5-directed CAR-T in which CD5 is deleted from the engineered cells; an open-label phase 1 study with the University of Pennsylvania in T-cell non-Hodgkin lymphoma (NCT06420089) dosed its first patient in December 2024. Further programmes VIPER-102 and VIPER-103 are listed. The chief executive and co-founder is Nicholas Siciliano. Its first registered cancer trial, NCT06420089, was posted on ClinicalTrials.gov in May 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.vittoriabio.com/"},{"label":"Pipeline","url":"https://vittoriabio.com/pipeline/"},{"label":"ClinicalTrials.gov: phase 1 trial of Senza5 CART5 (VIPER-101) in T-cell lymphoma (NCT06420089)","url":"https://clinicaltrials.gov/study/NCT06420089"}],"tags":[],"related":[],"cancers":["peripheral-t-cell-lymphoma"],"sections":["cell-therapy","immunotherapy"],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on 29 October 2026: vittoriabio.com home, about and pipeline pages. Founding year and financing not stated on the pages read. No CD5 target record exists in OnCo.","Trial facts from the ClinicalTrials.gov record NCT06420089, read on 29 October 2026."],"hq":"Philadelphia, PA","country":"US","companyType":"cell-therapy","website":"https://www.vittoriabio.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/vittoria-biotherapeutics/","neighbours":{"cancer":[{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}]}}